JPH0463053B2 - - Google Patents

Info

Publication number: JPH0463053B2
Authority: JP; Japan
Prior art keywords: copolymer; minutes; polyoxyethylene; urokinase; blood
Prior art date: 1982-09-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP57169160A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5959629A (ja

Inventor

Hajime Hiratani

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

JCR Pharmaceuticals Co Ltd

Original Assignee

JCR Pharmaceuticals Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-09-27

Filing date

1982-09-27

Publication date

1992-10-08

1982-09-27 Application filed by JCR Pharmaceuticals Co Ltd filed Critical JCR Pharmaceuticals Co Ltd

1982-09-27 Priority to JP57169160A priority Critical patent/JPS5959629A/ja

1983-06-23 Priority to DE8383303636T priority patent/DE3380726D1/de

1983-06-23 Priority to US06/507,154 priority patent/US4609546A/en

1983-06-23 Priority to EP83303636A priority patent/EP0098110B1/fr

1984-04-05 Publication of JPS5959629A publication Critical patent/JPS5959629A/ja

1992-10-08 Publication of JPH0463053B2 publication Critical patent/JPH0463053B2/ja

Status Granted legal-status Critical Current

Links

102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 11
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 11
229960005356 urokinase Drugs 0.000 claims description 11
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 8
229920001184 polypeptide Polymers 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
102000001399 Kallikrein Human genes 0.000 claims description 7
108060005987 Kallikrein Proteins 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
102000003886 Glycoproteins Human genes 0.000 claims description 6
108090000288 Glycoproteins Proteins 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 4
239000011230 binding agent Substances 0.000 claims description 4
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical group ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
UKYNESNNFCHAEV-UHFFFAOYSA-N 3,4-dibromooxolane-2,5-dione Chemical compound BrC1C(Br)C(=O)OC1=O UKYNESNNFCHAEV-UHFFFAOYSA-N 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
229940088598 enzyme Drugs 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
230000002459 sustained effect Effects 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
229940079322 interferon Drugs 0.000 claims 1
229920001577 copolymer Polymers 0.000 description 21
230000000694 effects Effects 0.000 description 16
239000013543 active substance Substances 0.000 description 13
238000000034 method Methods 0.000 description 13
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
102000006992 Interferon-alpha Human genes 0.000 description 5
108010047761 Interferon-alpha Proteins 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
230000002485 urinary effect Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
241001558496 Talpa caeca Species 0.000 description 2
241000711975 Vesicular stomatitis virus Species 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
-1 polyoxyethylene Polymers 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
URNKXHHGSVKUKV-HJOGWXRNSA-N (2s)-n-[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-2-[(4-methyl-2-oxochromen-7-yl)amino]pentanoyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](C(=O)NC(=O)[C@H](CCCN=C(N)N)NC1=CC=2OC(=O)C=C(C=2C=C1)C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 URNKXHHGSVKUKV-HJOGWXRNSA-N 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
102000009133 Arylsulfatases Human genes 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
LTLYEAJONXGNFG-DCAQKATOSA-N E64 Chemical compound NC(=N)NCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O LTLYEAJONXGNFG-DCAQKATOSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
229920002012 Pluronic® F 38 Polymers 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
241000700605 Viruses Species 0.000 description 1
SHOKWSLXDAIZPP-UHFFFAOYSA-N [4-(4-iodooxy-2-methyl-5-propan-2-ylphenyl)-5-methyl-2-propan-2-ylphenyl] hypoiodite Chemical compound C1=C(OI)C(C(C)C)=CC(C=2C(=CC(OI)=C(C(C)C)C=2)C)=C1C SHOKWSLXDAIZPP-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940015047 chorionic gonadotropin Drugs 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001914 filtration Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108010028105 prolyl-phenylalanyl-arginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
108060007951 sulfatase Proteins 0.000 description 1
108010088854 urinastatin Proteins 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP57169160A 1982-06-24 1982-09-27 効力持続性組成物 Granted JPS5959629A (ja)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
JP57169160A JPS5959629A (ja)	1982-09-27	1982-09-27	効力持続性組成物
DE8383303636T DE3380726D1 (en)	1982-06-24	1983-06-23	Long-acting composition
US06/507,154 US4609546A (en)	1982-06-24	1983-06-23	Long-acting composition
EP83303636A EP0098110B1 (fr)	1982-06-24	1983-06-23	Composition à action prolongée

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP57169160A JPS5959629A (ja)	1982-09-27	1982-09-27	効力持続性組成物

Publications (2)

Publication Number	Publication Date
JPS5959629A JPS5959629A (ja)	1984-04-05
JPH0463053B2 true JPH0463053B2 (fr)	1992-10-08

Family

ID=15881383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57169160A Granted JPS5959629A (ja)	1982-06-24	1982-09-27	効力持続性組成物

Country Status (1)

Country	Link
JP (1)	JPS5959629A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59172425A (ja) *	1983-03-18	1984-09-29	Nippon Chemiphar Co Ltd	新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4496689A (en) *	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB8430252D0 (en) *	1984-11-30	1985-01-09	Beecham Group Plc	Compounds
JPS61176532A (ja) *	1985-01-30	1986-08-08	Green Cross Corp:The	プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
EP0498470B1 (fr) *	1986-05-15	1996-09-11	Emory University	Composition pharmaceutique injectable pour la protection de tissus endammagés par l'ischémie
JPH07103158B2 (ja) *	1989-01-24	1995-11-08	電気化学工業株式会社	コロニー刺激因子―ゼラチン結合体
ES2312166T3 (es)	1994-02-23	2009-02-16	Kyowa Hakko Kogyo Co., Ltd	Acelerador del crecimiento plaquetario.
JP4610154B2 (ja) *	2002-05-30	2011-01-12	大塚製薬株式会社	注射用製剤
EA012205B1 (ru) *	2004-05-17	2009-08-28	Арес Трейдинг С.А.	Гидрогелевые препараты интерферона

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5612308A (en) *	1979-07-11	1981-02-06	Ajinomoto Co Inc	Blood substitute
JPS58225025A (ja) *	1982-06-24	1983-12-27	Nippon Chem Res Kk	効力持続性組成物

1982
- 1982-09-27 JP JP57169160A patent/JPS5959629A/ja active Granted

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5612308A (en) *	1979-07-11	1981-02-06	Ajinomoto Co Inc	Blood substitute
JPS58225025A (ja) *	1982-06-24	1983-12-27	Nippon Chem Res Kk	効力持続性組成物

Also Published As

Publication number	Publication date
JPS5959629A (ja)	1984-04-05

Publication	Publication Date	Title
US4609546A (en)	1986-09-02	Long-acting composition
JP7054407B2 (ja)	2022-04-13	オキシム連結のための求核触媒
EA014103B1 (ru)	2010-10-29	Конъюгат, включающий белок и полимер или его производное (варианты), способ его получения, применение конъюгата и содержащая его фармацевтическая композиция
AU2005225513B2 (en)	2012-01-12	Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
KR101832937B1 (ko)	2018-02-28	혈액 응고 단백질 복합체
EP0200467B1 (fr)	1990-12-27	Superoxyde dismutase combiné avec un oxyde de polyalkylène
JP7304402B2 (ja)	2023-07-06	オキシム連結のための求核触媒
JP3173794B2 (ja)	2001-06-04	タンパク質またはポリペプチド類とその製造法および中間化合物
US10350301B2 (en)	2019-07-16	Blood coagulation protein conjugates
JP2015512927A (ja)	2015-04-30	最適化された皮下治療薬
JPH0463053B2 (fr)	1992-10-08
US20190240295A1 (en)	2019-08-08	Factor viii with extended half-life and reduced ligand-binding properties
JPS58225025A (ja)	1983-12-27	効力持続性組成物
MXPA06010189A (en)	2007-04-20	Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination